Justin Oldham, MD, MS

The European Respiratory Society (ERS) Congress fosters collaboration among global experts, advancing respiratory health and promoting equality in medicine.

Nerandomilast for idiopathic pulmonary fibrosis potentially improves survival and slows disease progression, explains Justin Oldham, MD, PhD, MS, FIBRONEER steering committee member.

Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.

The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.

Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.